A Hailwt #6

RECEIVED
SEP 19 2000
TECH CENTER 1600/2900

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO.	APPLICATION NO.
MEWB25.001APC	09/403,440
APPLICANT: David P. Lane	
FILING DATE: January 19, 2000	GROUP: 1614

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
MDR	1	WO 93/20238	14.10.93	Patent Cooperation Treaty	C12Q	1/68		
	2	WO 96/02642	01.02.96	Patent Cooperation Treaty	C12Q	15/12		
	3	WO 98/01467	15.01.98	Patent Cooperation Treaty	C07K	14/00		

EXAMINER INITIAL		**OTHER DOCUMENTS** (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
MDR	4	Blaydes, et al., *Oncogene*, 14:1859-1568, 1997,
		"tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2."
	5	Böttger, et al., *Oncogene*, 13:2141-2147, 1996,
		"Identification of novel mdm2 binding peptides by phage display."
	6	Chen, et al., *Proc. Natl. Acad. Sci. USA*, 91:2684-2688, March 1994,
		"Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway."
	7	Colas, et al., *Nature*, 380:548-550, April 11, 1996,
		"Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2."
	8	Finlay, C.A., *Molecular and Cellular Biology*, 13(1):301-306, January 1993,
		"The mdm-2 Oncogene Can Overcome Wild-Type p53 Suppression of Transformed Cell Growth."
	9	Florenes, et al., *Journal of the National Cancer Institute*, 86(17):1297-1302, September 7, 1994,
		"MDM2 Gene Amplification and Transcript Levels in Human Sarcomas: Relationship to TP53 Gene Status."
	10	Haupt, et al., *The EMBO Journal*, 15(7):1596-1606, 1996,
		"Cell type-specific inhibition of p53-mediated apoptosis by mdm2."
	11	Hupp, et al., *Cell*, 83:237-245, October 20, 1995,
		"Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53."
	12	Jones, et al., *Nature*, 378:206-208, November 9, 1995,
		"Rescue of embryonic lethality in Mdm1-deficient mice by absence of p53."
	13	Juven, et al., *Oncogene*, 8:3411-3416, 1993,
		"Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene."
	14	Kovar, et al., *Oncogene*, 8:2683-2690, 1993,
		"Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumors."

EXAMINER	M. T DAVIS	DATE CONSIDERED	02/15/03

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MEWB25.001APC	SERIAL NO. 09/403,440
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT David P. Lane	
	FILING DATE January 19, 2000	GROUP 1614

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	15	Kussie et al., *Science*, 274:948-953, November 8, 1996, "Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain."
	16	LaVallie, et al., *Bio/Technology*, 11:187-193, February 11, 1993, "A Thioredoxin Gene Fusion Expression System the E. coli Cytoplasm."
	17	Lin, Y. and M. Green, *Nature*, 340:656-659, August 24, 1989, "Similarities between prokaryotic and eukaryotic cyclic AMP-responsive promoter elements."
	18	Lu, X and D. Lane, *Cell*, 75:765-778, November 19, 1993, "Differential Induction of Transcriptionally Active p53 Following UV or Ionizing Radiation: Defects in Chromosome Instability Syndromes?"
	19	Marston, et al., *Oncogene*, 9:2707-2716, 1994, "Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function."
	20	Midgley, et al., *Journal of Cell Science*, 101:183-189, 1992, "Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli."
	21	Momand, et al., *Cell*, 69:1237-1245, June 26, 1992, "The mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation."
	22	Montes de Oca Luna, et al., *Nature*, 278:203-206, 1995, "Rescue of Early Embryonic Lethality in mdm1-Deficient *."
	23	Oliner, et al., *Nature*, 362:857-860, April 29, 1993, "Oncoprotein MDM1 conceals the activation domain of tumour suppressor p53."
	24	Otto A. and W. Deppert, *Oncogene*, 8:2591-2603, 1993, "Upregulation of mdm-2 expression in meth a tumor cells tolerating wild-type p53."
	25	Picksley, et al., *Oncogene*, 9:2523-2529, 1994, "Immunochemical analysis of the interaction of p53 with MDM2; - fine mapping of the MDM2 binding site on p53 using synthetic peptides."
	26	Renzing, J. and D. Lane, *Oncogene*, 10:1865-1868, 1995, "p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts."
	27	Vojtesek, B. and D. Lane, *Journal of Cell Science*, 105:607-612, 1993, "Regulation of p53 protein expression in human breast cancer cell lines."
	28	Wu, et al., *Genes & Development*, 7:1126-1132, 1993, "The p53-mdm-2 autoregulatory feedback loop."

W:\DOCS\GRD\GRD-3120.DOC
081500

EXAMINER M. T. DAVIS	DATE CONSIDERED 02/15/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.